Parabilis Medicines Quarterly Income Statement
NASDAQ: PBLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.48-0.61 (-2.17%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Parabilis Medicines revenue and earnings
In the quarter ended Jun 30, 2026, Parabilis Medicines generated $148,000 in revenue. Parabilis Medicines reported a net loss of $52.5 million. Operating margin was -34382.4%.
Diluted earnings per share came in at -$2.32.
Summary generated from market data by MetaCap's automated system. Methodology
Parabilis Medicines income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q? 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Revenue | 148.00K | — | 0 | — |
| Revenue growth (YoY) | — | — | — | — |
| Operating Expenses | 51.03M | — | 36.52M | — |
| Research & Development | 39.38M | — | 30.13M | — |
| Operating Income | -50.89M | — | -36.52M | — |
| Interest Expense | 210.00K | — | 396.00K | — |
| Other Income (Expense) | -1.58M | — | 1.71M | — |
| Net Income | -52.46M | -45.32M | -34.81M | -38.33M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -2.32 | — | -22.28 | — |
| EPS (Diluted) | -2.32 | — | -22.28 | — |
| Shares Outstanding (Basic) | 28.91M | — | 2.02M | — |
| Shares Outstanding (Diluted) | 28.91M | — | 2.02M | — |
| EBITDA | -50.29M | — | -36.32M | — |
| Operating Margin | -34382.43% | — | — | — |
| Net Margin | -35447.97% | — | — | — |
This table shows 4 quarterly periods of Parabilis Medicines's income statement, from Q2 2026 back to Q? 2025, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow PBLS's reporting calendar. What is a income statement?